Cell therapeutics' pixuvri approved in european union as monotherapy to treat adult patients with multiply relapsed or refractory aggressive non-hodgkin b-cell lymphomas

Cell Therapeutics, 05/11/2012

Cell Therapeutics, Inc. announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non–Hodgkin B–cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting.

Print Article Summary